• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

曲妥珠单抗在胃食管癌治疗中的应用：患者选择与展望

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives.

作者信息

Davidson Michael, Starling Naureen

机构信息

Department of Gastrointestinal Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.

出版信息

Onco Targets Ther. 2016 Nov 25;9:7235-7245. doi: 10.2147/OTT.S100643. eCollection 2016.

DOI:10.2147/OTT.S100643
PMID:27932891
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5135398/
Abstract

The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.

摘要

在晚期胃癌和胃食管交界癌的一部分HER2阳性患者的治疗中添加曲妥珠单抗已显示出临床获益；然而，在定义和选择此类患者的最佳方法上仍存在问题。本综述概述了评估HER2阳性的当前标准、HER2阳性胃癌和食管癌不断变化的治疗格局以及HER2靶向治疗最佳患者选择中的挑战和潜在未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f1/5135398/29c97207b36a/ott-9-7235Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f1/5135398/f7cbecaac5b7/ott-9-7235Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f1/5135398/d672575470f4/ott-9-7235Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f1/5135398/056f74f5ec52/ott-9-7235Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f1/5135398/29c97207b36a/ott-9-7235Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f1/5135398/f7cbecaac5b7/ott-9-7235Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f1/5135398/d672575470f4/ott-9-7235Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f1/5135398/056f74f5ec52/ott-9-7235Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f1/5135398/29c97207b36a/ott-9-7235Fig4.jpg

相似文献

1
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives.曲妥珠单抗在胃食管癌治疗中的应用：患者选择与展望
Onco Targets Ther. 2016 Nov 25;9:7235-7245. doi: 10.2147/OTT.S100643. eCollection 2016.
2
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.曲妥珠单抗治疗后HER2阳性胃癌或胃食管癌中HER2缺失：对进一步临床研究的意义
Int J Cancer. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. Epub 2016 Sep 16.
3
Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.HER2 阳性晚期胃癌和胃食管交界癌的治疗进展。
J Clin Gastroenterol. 2012 Sep;46(8):637-48. doi: 10.1097/MCG.0b013e3182557307.
4
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.胃/胃食管癌中的HER2异质性：从实验室到临床实践
World J Gastroenterol. 2016 Jul 14;22(26):5879-87. doi: 10.3748/wjg.v22.i26.5879.
5
Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.晚期胃癌和胃食管癌中HER2阳性的局部和中心评估及临床结果——来自AGMT GASTRIC-5注册研究的结果
J Clin Med. 2020 Mar 29;9(4):935. doi: 10.3390/jcm9040935.
6
HER2 testing in gastric and gastroesophageal adenocarcinomas.胃及胃食管腺癌中的HER2检测
Adv Anat Pathol. 2015 May;22(3):194-201. doi: 10.1097/PAP.0000000000000067.
7
[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].[人表皮生长因子受体2与胃癌：曲妥珠单抗的新型治疗靶点]
Bull Cancer. 2010 Dec;97(12):1429-40. doi: 10.1684/bdc.2010.1224.
8
Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.胃食管腺癌中HER2阳性的病理诊断
Am J Clin Pathol. 2015 Feb;143(2):257-64. doi: 10.1309/AJCPCX69HGDDGYCQ.
9
A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.胃/胃食管结合部癌中 HER2 检测的生存指南。
Gastrointest Endosc. 2019 Jul;90(1):44-54. doi: 10.1016/j.gie.2019.03.022. Epub 2019 Mar 28.
10
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.EORTC-1203-GITCG - “创新”试验：曲妥珠单抗单药与曲妥珠单抗加帕妥珠单抗联合化疗在 HER2 阳性胃和胃食管交界处腺癌围手术期治疗中的疗效对比：EORTC 胃肠道肿瘤研究组、韩国癌症研究组和荷兰上消化道肿瘤组的一项随机 II 期分组试验。
BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.

引用本文的文献

1
A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs.一种新型抗HER2/EGFR双特异性抗体药物偶联物显示出有前景的抗肿瘤疗效，并克服了对HER2或EGFR靶向ADC的耐药性。
Invest New Drugs. 2025 Apr;43(2):262-275. doi: 10.1007/s10637-025-01507-w. Epub 2025 Feb 21.
2
Blocking the Hormone Receptors Modulates NLRP3 in LPS-Primed Breast Cancer Cells.阻断激素受体可调节 LPS 预刺激的乳腺癌细胞中的 NLRP3。
Int J Mol Sci. 2023 Mar 2;24(5):4846. doi: 10.3390/ijms24054846.
3
High-throughput membrane-anchored proteome screening reveals PIEZO1 as a promising antibody-drug target for human esophageal squamous cell carcinoma.

本文引用的文献

1
HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study.HER2在胃癌和胃食管交界癌中的状态：大型跨国HER-EAGLE研究的结果。
Appl Immunohistochem Mol Morphol. 2018 Apr;26(4):239-245. doi: 10.1097/PAI.0000000000000423.
2
Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.曲妥珠单抗在HER2阳性晚期胃癌疾病进展后的疗效：一项多中心前瞻性观察队列研究
Oncotarget. 2016 Aug 2;7(31):50656-50665. doi: 10.18632/oncotarget.10456.
3
Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.
高通量膜锚定蛋白质组筛选揭示 PIEZO1 是人食管鳞状细胞癌有前途的抗体药物靶标。
Cancer Med. 2022 Oct;11(19):3700-3713. doi: 10.1002/cam4.4744. Epub 2022 May 24.
4
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy.治疗前中性粒细胞与淋巴细胞比值作为不可切除或转移性食管癌患者接受抗PD-1治疗时的预后生物标志物
Front Oncol. 2022 Apr 13;12:834564. doi: 10.3389/fonc.2022.834564. eCollection 2022.
5
Downregulation of miR-375 contributes to ERBB2-mediated VEGFA overexpression in esophageal cancer.miR-375的下调促进了食管癌中ERBB2介导的VEGFA过表达。
J Cancer. 2021 Oct 20;12(23):7138-7146. doi: 10.7150/jca.63836. eCollection 2021.
6
Advances in targeted therapy for esophageal cancer.食管癌的靶向治疗进展。
Signal Transduct Target Ther. 2020 Oct 7;5(1):229. doi: 10.1038/s41392-020-00323-3.
7
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review.HER2突变的非小细胞肺癌进展后给予多线抗HER2治疗是否有作用？病例报告及文献综述
Oncol Ther. 2020 Dec;8(2):341-350. doi: 10.1007/s40487-020-00121-5. Epub 2020 Jul 7.
8
Xanthohumol Inhibits the Growth of Keratin 18-Overexpressed Esophageal Squamous Cell Carcinoma and .黄腐酚抑制角蛋白18过表达的食管鳞状细胞癌的生长 以及 。（原文此处不完整）
Front Cell Dev Biol. 2020 May 19;8:366. doi: 10.3389/fcell.2020.00366. eCollection 2020.
9
Esophageal cancer research today and tomorrow: Lessons from algae and other perspectives.食管癌研究的今昔与未来：来自藻类及其他视角的经验教训
AIMS Genet. 2018 Mar 7;5(1):75-90. doi: 10.3934/genet.2018.1.75. eCollection 2018.
10
"Targeted" Chemotherapy for Esophageal Cancer.食管癌的“靶向”化疗
Front Oncol. 2017 Apr 3;7:63. doi: 10.3389/fonc.2017.00063. eCollection 2017.
接受曲妥珠单抗治疗的乳腺癌患者常规心脏监测的临床应用价值
Ann Pharmacother. 2016 Sep;50(9):712-7. doi: 10.1177/1060028016654160. Epub 2016 Jun 15.
4
Pertuzumab and trastuzumab: the rationale way to synergy.帕妥珠单抗和曲妥珠单抗：协同作用的合理方式。
An Acad Bras Cienc. 2016;88 Suppl 1:565-77. doi: 10.1590/0001-3765201620150178.
5
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.曲妥珠单抗联合拉帕替尼治疗经治、KRAS 密码子 12/13 野生型、HER2 阳性转移性结直肠癌（HERACLES）：一项概念验证、多中心、开放标签、Ⅱ期临床试验。
Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20.
6
Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer.采用液滴数字PCR技术监测胃癌患者循环肿瘤DNA中的HER2拷贝数状态。
Gastric Cancer. 2017 Jan;20(1):126-135. doi: 10.1007/s10120-016-0599-z. Epub 2016 Feb 13.
7
Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.癌症治疗相关的心脏功能障碍与心力衰竭：第2部分：预防、治疗、指南及未来方向。
Circ Heart Fail. 2016 Feb;9(2):e002843. doi: 10.1161/CIRCHEARTFAILURE.115.002843.
8
Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).在初始HER2阴性原发性肿瘤的晚期胃癌中，通过对原发灶和转移灶进行HER2重新评估获得HER2阳性病例的额外收益：胃癌HER2重新评估研究1（GASTHER1）的结果
Eur J Cancer. 2016 Jan;53:42-50. doi: 10.1016/j.ejca.2015.09.018. Epub 2015 Dec 13.
9
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.拉帕替尼联合卡培他滨和奥沙利铂治疗人表皮生长因子受体 2 阳性的晚期或转移性胃、食管或胃食管交界腺癌：TRIO-013/LOGiC——一项随机 III 期试验。
J Clin Oncol. 2016 Feb 10;34(5):443-51. doi: 10.1200/JCO.2015.62.6598. Epub 2015 Nov 30.
10
Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.预测胃癌切除标本中HER2状态的活检肿瘤碎片理想数量
Oncotarget. 2015 Nov 10;6(35):38372-80. doi: 10.18632/oncotarget.5368.